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REVIEW

Emergency Medicine Journal Club
Dave M. Gibbs*, Dylan Norton, Kyle Barbour
Rochester Regional Health, USA

Abstract
In this column, we provide a brief review of important papers recently published that relate to the ﬁeld of Emergency
Medicine. The goal is to provide the busy clinician a bullet-like summary of the study, focusing on the research
question, methods, results, limitations and bottom line interpretation.
Keywords: Emergency medicine, Evidence based medicine, Journal club, Review

1. Topic: Pulmonary embolism, decision rules
Question: To exclude pulmonary embolism without
imaging in PERC-positive patients, is a combined
YEARS and age-adjusted D-dimer approach noninferior to age-adjusted D-dimer alone?
Study: Freund Y et al. Effect of a diagnostic
strategy using an elevated and age-adjusted Ddimer threshold on thromboembolic events in
emergency department patients with suspected
pulmonary embolism: a randomized clinical trial.
JAMA. 2021; 326(21):2141e2149. https://doi.org/10.
1001/jama.2021.20750.
Methods: Multicenter, prospective, cluster randomized, crossover, noninferiority trial of low to
intermediate risk patients for pulmonary embolism
(PE) by clinician gestalt across 18 emergency departments in France and Spain from 2019 to 2020.
The control arm used age-adjusted D-dimer alone
(threshold ¼ age  10 ng/mL if age 50, 500 ng/mL
otherwise), with positive patients receiving chest
imaging (CT angiogram or VQ scintigraphy). The
intervention arm ﬁrst evaluated YEARS score (0e3,
1 point each for PE most likely, hemoptysis, or signs
of DVT); if YEARS was positive, age-adjusted Ddimer threshold was used, if 0, threshold was set to
1000 ng/mL (see ﬂowchart below created for this
review, not from the original paper). Patients at high
risk, at low risk who were also PERC negative, who
had obvious alternate diagnoses, were pregnant, or

who were on anticoagulation were excluded.
Participating EDs were randomized to use the
intervention or control approach for all appropriate
patients for 4 months, then switched to the alternate
approach after a 2 month washout period. Patients
were followed up after 3 months to identify diagnostic failures.
Results: 1414 patients were enrolled, 726 in the
intervention arm, 688 in the control arm and
analyzed as-enrolled. An additional analysis was
performed after excluding 39 patients for protocol
deviations and 67 incorrectly-enrolled patients in a
per-protocol analysis. PE was diagnosed in the ED
in 100 patients, 7.4% and 6.7% of the intervention
and control groups, respectively. Up to 9 PEs were
missed in the as-enrolled group (3 in intervention
arm, 6 in control arm), including 5 deaths due to
unknown cause, a failure rate of 0.15% and 0.80% in
the intervention and control groups respectively. No
PEs were missed in patients with YEARS score 0 in
the intervention arm, the only group whose management was different between intervention and
control. Chest imaging was 14.3% less in the intervention group (1 in 7 patients). For another, more
detailed summary, see the analysis in RebelEM.
Limitations: European setting may be different
from American patients and practice; protocol relied
on emergency physician gestalt which may not be
generalizable to residents, non-EM physicians, or
non-physicians; pregnant patients were excluded;
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randomization occurred at the center and not patient level; some selection bias likely; moderate
number of protocol errors (7.5% of all patients),
unclear handling of intermediate-probability VQ
scans.
Bottom Line: In this well-designed study,
combining the YEARS score and age-adjusted Ddimer to exclude PE without imaging was noninferior to age-adjusted D-dimer alone and reduced
need for chest imaging.

2. Topic: Nephrology, bias, health equity
Question: Should calculations of estimated
glomerular ﬁltration rate (eGFR) exclude race, and if
so, how should eGFR be calculated?
Study: Delgado C, Baweja M, Crews DC et al. A
unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on reassessing
the inclusion of race in diagnosing kidney disease.
Am J Kidney Dis. 2022; 79(2):268e288.e1. https://doi.
org/10.1053/j.ajkd.2021.08.003.
Methods: Evidence-based review by expert task
force convened by the National Kidney Foundation
and American Society of Nephrology. Evidence
was reviewed over 10 months and incorporated
feedback from patients, clinicians, health equity
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experts, and reviews of interim reports. For background, standard eGFR calculations include a race
coefﬁcient that increases the eGFR for a given
creatinine in Black patients, including the standard
CKD-EPI and earlier MDRD equations. The race
coefﬁcient is especially concerning given the long
history of racism in medicine and present reality
that Black patients have longer delays, worse outcomes, and face more barriers in nearly all aspects
of medicine, including nephrology care.
Results: 26 eGFR calculations were reviewed,
including those which are based on cystatin C, b2
microglobulin, and other non-creatinine ﬁltration
markers. Non-creatinine markers were excluded
after review due to feasibility and implementation
concerns. Calculations were compared based on
accuracy of predicting measured GFR and examined
for bias. The task force found that current research
demonstrates that cohorting patients into Black and
non-Black populations poorly reﬂects underlying
biologic reality and inserts racial bias into major
medical decisions. They found that the race coefﬁcient fails to resolve discrepancies between eGFR
and measured GFR, and increasing the eGFR for a
given creatinine means that Black patients are less
likely to have early diagnosis of chronic kidney
disease, referral for dialysis, or referral for
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transplant. Of all the considered approaches, the
task force determined that the best option was the
CKD-EPIcr_R equation, identical to the currently
used CKD-EPI equation but without the race
coefﬁcient.
Limitations: No current eGFR calculation is
known to be accurate in all groups and easily
implementable, CKD-EPIcr_R is the task force's
conclusion as to the least worst option, sharing its
inaccuracies equally across ethnic groups. Usual
caveats regarding the limitations of estimates apply.
In particular, all eGFR calculations presume stable
renal function, which is deﬁnitionally not the case in
emergency patients with acutely abnormal renal
function.
Bottom Line: Race should not factor into eGFR
calculations. Calculations of eGFR are already
imperfect due to the complexities of kidney ﬁltration; the race coefﬁcient failed to resolve these imperfections and introduced new, racially biased
errors. CKD-EPI without the race coefﬁcient is the
current best estimate available by expert consensus.
Other approaches, such as using cystatin C, can be
more accurate but are not available in the emergency medicine context. Within Rochester Regional
Health, GFR calculations will use the new equation
beginning March 1, 2022.

3. Topic: Abdominal pain
Question: What are the long-term outcomes of
appendicitis treated with antibiotics vs surgical
management?
Study: Antibiotics versus Appendectomy for
Acute Appendicitis - Longer-Term Outcomes. N
Engl J Med. 2021 Dec 16; 385(25):2395e2397.
Methods: This is a follow-up letter describing
long-term outcomes of up to four years for patients
with appendicitis treated with antibiotics alone. The
letter updates data from the Comparison of Outcomes of Antibiotic Drugs and Appendectomy trial
(CODA) which initially showed that treatment of
appendicitis with antibiotics was non-inferior to
surgery at 30 days.
Results: In the antibiotics groups, the percentage
of patients who underwent subsequent appendectomy was 40% (95% CI, 36e44%) at 1 year and 46%
(95% CI, 42e49%) at 2 years. The percentage was
49% (95% CI, 44e53%) at 3 and 4 years, according to
limited longer-term follow-up. By two years, 14% of
patients had required a second course of antibiotics.
Patients with an appendicolith were more likely to
require appendectomy, especially in the short term.
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Limitations: A large number of patients were lost
to follow-up, calling into question the reliability of
the long-term results.
Bottom Line: In a group of adults treated with
antibiotics, 49% of patients required appendectomy
at four years. These results suggest antibiotic management may be reasonable in select patients with
appendicitis, but providers should consider patient
speciﬁc factors and utilize shared decision making
when determining which patients are best suited for
antibiotic management.

4. Topic: Radiology/Neurology
Question: Is it possible to rule out aneurysmal
subarachnoid hemorrhage (aSAH) using multislice
CT scanning (MSCT) out to 24 h after headache
onset?
Study: Vincent A et al. Sensitivity of modern
multislice CT for subarachnoid haemorrhage at incremental timepoints after headache onset: a 10year analysis. Emerg Med J. 2021 Nov 24:emermed2020-211,068.
Methods: Retrospective analysis of data from a
single hospital in Christchurch New Zealand for
patients diagnosed with SAH between 2008 and
2017.347 patients met inclusion criteria. 260 had
aSAH and of those, 97.3% had a positive MSCT.
Time to MSCT was deﬁned as the duration of
headache onset to CT.
Results: Sensitivity for detection of aSAH
decreased over time: at 6, 12, 24, 48, 72 and 96 h post
headache onset the sensitivity was 100%
(98.0e100%), 100% (98.2e100%), 100% (98.3e100%),
99.6% (97.6e100%), 99.6% (97.6e100%), and 98.7%
(96.4e99.7%), respectively.
Limitations: Authors relied on the ﬁnal diagnosis
of SAH as inclusion criteria and patients with SAH
may have been missed if they were not eventually
diagnosed with SAH on the initial encounter or
follow up. Authors believe this is unlikely as they
cross checked mortality data and there is only one
hospital in this metropolitan area. Additionally, this
is retrospective data.
Bottom Line: This study adds to the growing
data supporting a longer time window to rule out
aSAH based on trained radiologist interpretation
of modern generation CT scans. Debate will
continue as to whether LP or CT angiogram
should be performed to deﬁnitively exclude
aneurysmal hemorrhage in high risk cases, and it
is clear that sensitivity of plain CT decreases over
time.
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5. Topic: Hematology
Question: What are some strategies to manage
anemic patients in the Emergency Department who
cannot receive blood transfusions?
Study: Johnson-Arbor K et al. Bloodless Management of the Anemic Patient in the Emergency
Department. Ann Emerg Med 2022 Jan; 79(1):48e57.
doi: 10.1016/j.annemergmed.2021.06.015.
Methods: Review article of the ED management of
anemia in those that cannot receive blood transfusions due to religious reasons, blood scarcity, or
autoimmune hemolysis.
Recommendations:
1. Reduce Unnecessary Blood loss. They recommend using small vacutainers, limited to only
the essential labs. Avoid ordering hold tubes.
Additionally, if the patient has active bleeding
they emphasize immediate control of bleeding
whether that means early surgical or procedural
intervention (ie EGD), and rapid correction of
coagulopathy. Use of recombinant factor VII
(derived from hamster serum), along with
bleeding control, has been used in patients who
cannot receive blood products. TXA has been
used to control bleeding in a variety of conditions, with varying levels of efﬁcacy. Also
consider autologous autotransfusion if the
means of doing so are available at your facility.
2. Enhance Red Cell Production. Consider early
administration of erythropoietin, or other similar
products to enhance marrow production of
RBCs.
3. Increase O2 Carrying Capacity of Blood.
Consider administration of synthetic hemoglobin products, or transfer to a facility with hyperbarics to increase the patient's oxygen
carrying capacity.
4. Interpersonal Interactions. The authors caution
providers to avoid chastizing their patients over
religious decisions to not receive blood products, and to obtain an ethics consult should
they care for an unresponsive/incapacitated
patient who would otherwise not receive blood
products if they were capable of making
decisions.
5. Consider developing hospital guidelines for
dealing with bloodless patients. This may facilitate them receiving alternative treatments, and
streamline their care.
Bottom Line: Anemic patients who cannot receive
blood products are clinically challenging to manage,
and the authors summarize a number of ways in
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which providers can provide care beyond blood
transfusion.

6. Topic: Pediatrics
Question: Does IV magnesium worsen outcomes
in pediatric asthma?
Study: Arnold D et al. Prospective Observational
Study of Clinical Outcomes After Intravenous
Magnesium for Moderate and Severe Acute Asthma
Exacerbations in Children
Methods: Secondary analysis of prospective
observational data from children 5 to 17 with moderate to severe asthma exacerbations. Outcomes
measured were change in Acute Asthma Intensity
Research Score, hospitalizations, and time to
spacing to 4 h for albuterol treatments.
Results: Among 301 children, median age was 8.1
(6.4e10.2) years, and 84 received IV-Mg (28%). In a
propensity score covariate-adjusted multivariable
linear regression model, IV-Mg treatment was
associated with a 2-h increase in the Acute Asthma
Intensity Research Score (b-coefﬁcient ¼ 0.98; 95%
conﬁdence interval [CI], 0.20e1.77), indicating
increased exacerbation severity. Three additional
PS-based models yielded similar results. Participants receiving IV-Mg had 5.8-fold (95% CI,
2.8e11.9) and 6.8-fold (95% CI, 3.6e12.9) greater
odds of hospitalization in PS-based multivariable
regression models. Among hospitalized participants, there was no difference in time to albuterol of
every 4 h or more in a PS covariate-adjusted Cox
proportional hazards model (hazard ratio ¼ 1.2; 95%
CI, 0.8e1.8).
Limitations: Secondary analyses are prone to bias,
and the patients were not randomized to IV magnesium. It could be that the receivers of IV magnesium were a sicker cohort that was not detected due
to unmeasured variables in the propensity score
models.
Bottom Line: IV magnesium was associated with
worsening asthma severity, however there were
several trial limitations and more information on the
topic is needed.

7. Topic: Resuscitation, airway
Question: Does use of a bougie increase the likelihood of ﬁrst pass intubation success compared to
stylet?
Study: Driver BE, Semler MW, Self WH et al. Effect of use of a bougie vs endotracheal tube with
stylet on successful intubation on the ﬁrst attempt
among critically ill patients undergoing tracheal
intubation: a randomized clinical trial. JAMA. 2021;
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326(24):2488e2497.https://doi.org/10.1001/jama.
2021.22002.
Methods: Multicenter, randomized, prospective
clinical trial. Patients were eligible if intubation with
a Macintosh or Miller blade was planned by the
clinician and were not pregnant, incarcerated, or
requiring immediate intubation without time for
randomization. Clinicians could exclude patients if
they felt that either of a bougie or stylet was
required or contraindicated. Medications, such as
paralytic and sedative choice, were chosen by the
intubator as they felt appropriate. The primary
outcome was ﬁrst-pass success; secondary outcome
was incidence of SpO2 < 80%.
Results: 1102 patients out of 1558 screened were
included across 7 emergency departments and 8
intensive care units at 11 hospitals in the United
States. A video laryngoscope was used for a majority
of patients (75.7% in bougie patients, 73.8% with
stylet patients). Successful ﬁrst-pass intubation
occurred in 80.4% of bougie patients and 83.0% of
stylet patients. Hypoxia occurred in 11.0% of bougie
patients and 8.8% of stylet patients. For additional
analysis in print and podcast form, see RebelEM.
Limitations: Clinicians could override randomization, acutely decompensating patients were
excluded, low baseline ﬁrst-pass success rate, low
intubator experience with bougies (median of 10
prior uses) and low experience overall (median of 60
prior intubations), video laryngoscopy was used a
majority of the time limiting generalizability to
direct laryngoscopy, most intubators were residents,
only 62.9% were emergency physicians.
Bottom Line: Routine use of a bougie did not
signiﬁcantly change ﬁrst-pass intubation success.
However, the study has signiﬁcant limitations
reducing its generalizability, particularly to direct
laryngoscopy where bougies are frequently used,
and to acutely decompensating patients who were
excluded.

ahead of print, 2021 Dec 21]. Ann Emerg Med. 2021;
S0196-0644(21)01461-X.
Methods: Meta-analysis of randomized controlled
trials for primary headache (migraine, tension, or
cluster headaches). Included regional anesthesia
techniques were sphenopalatine ganglion blocks
and greater occipital nerve blocks using either
lidocaine or bupivacaine. Studies compared
regional anesthesia to placebo or standard medication therapy (dopamine antagonists, non-steroidal
anti-inﬂammatories, or triptans).
Results: 11 studies were included; 10 were doubleblinded, 1 was single-blinded. Sphenopalatine
ganglion blocks were mostly delivered via intranasal droplets, but some were using a commercial
device speciﬁc for this purpose. Greater occipital
nerve blocks were performed using a standard syringe and small gauge needle. Pain scores were
overall signiﬁcantly lower in the treatment arms at
1, 5, 15, and 30 min intervals compared to placebo;
inconsistency of time point measurement precluded
comparison to standard treatment across studies.
Risk of bias was low to moderate overall; repeat
analysis after excluding high risk of bias studies did
not meaningfully change results. No serious adverse
events occurred; the most common events were injection site pain and dizziness. Only 2 studies evaluated repeat visits to the ED, one of which found
higher occurrence in the regional anesthesia group,
the other had no repeat visits.
Limitations: Analysis was only able to draw conclusions when compared to placebo, not standard
treatment, duration of effect past 30 min was not
evaluated, limited number of studies overall, heterogeneity of studies limits conclusions.
Bottom Line: Regional anesthesia may be effective
for treatment of primary headaches. However, its
efﬁcacy compared to standard treatment approaches remains unclear.

9. Topic: Resuscitation
8. Topic: Neurology, regional anesthesia
Question: Are peripheral nerve blocks effective
for primary headaches?
Study: Patel D, Yadav K, Taljaard M, Shorr R,
Perry JJ. Effectiveness of peripheral nerve blocks for
the treatment of primary headache disorders: a
systematic review and meta-analysis [published
online ahead of print, 2021 Oct 28]. Ann Emerg Med.
2021; S0196-0644(21)00794e0. https://doi.org/10.
1016/j.annemergmed.2021.08.007. Associated editorial: Friedman BW. Peripheral nerve blocks for
headache: a precise approach to pain management
in the emergency department [published online

Published by RocScholar, 2022

Question: Is there a lower incidence of acute
kidney injury or death in critically ill adults treated
with balanced multielectrolyte solution (BMES) vs.
normal saline?
Study: Finfer S et al. PLUS Study Investigators
and Australian New Zealand Intensive Care Society
Clinical Trials Group. Balanced Multielectrolyte
Solution versus Saline in Critically Ill Adults. N Engl
J Med. 2022 Mar 3; 386(9):815e826. https://doi.org/
10.1056/NEJMoa2114464. Epub 2022 Jan 18.
Methods:Double-blind randomized study. Critically ill ICU patients were randomized to receive
BMES (Plasma-Lyte 148) or 0.9% normal saline.
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Primary outcome was death from any cause within
90 days. Secondary outcomes included receipt of
new renal-replacement therapy and the maximum
increase in creatinine level during ICU stay.
Results: 5037 patients in Australia and New Zealand were included. Death occurred in 530 of 2433
patients (21.8%) in the BMES group and in 530 of
2413 patients (22.0%) in the saline group. There was
no statistical difference in creatinine increase between groups. No difference in adverse and serious
adverse events was noted. Median amount of ﬂuid
given was 3.9 L. About 30% of patients were
admitted to ICU from the ED, while the remainder
came from the hospital ﬂoor or surgery. Just over
40% of patients had sepsis.
Limitations: These were ICU patients with only
30% or so admitted from the ED. Many patients
received ﬂuids prior to admission to ICU and 5% of
the BMES group received >500 mL saline prior to
randomization. Over half of the patients in the
BMES group received greater than 500 cc of saline
due to medication infusions. The large amount of
saline administered to patients in the BMES group
may have attenuated the beneﬁt of BMES.
Bottom Line: There was no difference in the outcomes of death or kidney injury between patients
given BMES when compared to normal saline. Results are consistent with those from the recent BaSICS trial. There is likely no signiﬁcant beneﬁt to
balanced crystalloids when compared to normal
saline, and no compelling reason to choose balanced
ﬂuids for most patients undergoing resuscitation in
the ED.

10. Topic: Cardiology/Resuscitation
Question: Does the timing of ECG acquisition
affect the diagnostic accuracy of ECG for STEMI in
patients with return of spontaneous circulation
(ROSC) following out-of-hospital cardiac arrest
(OHCA)?
Study: Baldi E, Association of Timing of Electrocardiogram Acquisition After Return of Spontaneous Circulation With Coronary Angiography
Findings in Patients With Out-of-Hospital Cardiac
Arrest. JAMA NetwOpen. 2021 Jan 4; 4(1):e2032875.
https://doi.org/10.1001/jamanetworkopen.2020.
32875.
Methods: Retrospective, multicenter cohort study
conducted in 3 centers in Europe of adult patients
with OHCA due to a medical cause and ROSC
achieved in the emergency department. Only patients who had both a post-ROSC ECG and angiography
performed
were
included.
Two
cardiologists blinded to the angiography results and
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ECG timing independently evaluated the ECGs for
STEMI criteria. Patients with an ECG demonstrating
STEMI and an obstructive coronary lesion requiring
percutaneous coronary angioplasty (PTCA) were
classiﬁed as true positives, with those without an
obstructive lesion requiring intervention were classiﬁed as negatives.
Results: 370 of 586 eligible patients were included.
Median age was 62 years. The percentage of falsepositive ECG ﬁndings was signiﬁcantly higher in
the group with an ECG obtained in 7 min or less
(18.5%) as compared to those who received an ECG
later after ROSC (7.2% at 8e33 min and 5.8% at time
>33 min).
Limitations: Retrospective study with small sample size. Outcome was not the identiﬁcation of an
obstructive culprit lesion, but rather the performance of angioplasty. There could have been confounders which led to the delay of timing of postROSC ECG in some cases and it is unclear why
>33 min elapsed after ROSC prior to obtaining an
ECG in many patients. A large number of patients
never had a post-ROSC ECG performed and were
excluded.
Bottom Line: There may be a beneﬁt in waiting
several minutes after ROSC to obtain an ECG or
obtaining serial ECGs in certain patients with
ROSC. ST changes consistent with STEMI may be
due to global ischemia or other metabolic derangements in the period immediately following
ROSC and may not be indicative of a coronary
lesion amenable to angioplasty. It would be wise
to discuss all these cases with the interventionalist
before determining whether or not the patient
requires immediate angiography if early ST
changes consistent with STEMI normalize post
ROSC.

11. Topic: ENT
Question: Is topical tranexamic acid (TXA) effective for the management of epistaxis?
Study: Janapala RN et al. Efﬁcacy of topical tranexamic acid in epistaxis: A systematic review and
meta-analysis. Am J Emerg Med. 2022 Jan;
51:169e175.
Methods: Systematic review and meta-analysis
searching PubMed and Scopus databases for randomized controlled and observational studies on
TXA for the management of epistaxis. Primary
outcome was cessation of bleeding at the ﬁrst
assessment.
Secondary
outcomes
included
rebleeding at 24e72 h and again at 7e8 days.
Random effects model was used to calculate odds
ratio.
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Results: There were eight studies in the analysis,
including seven randomized trials and one retrospective study including 1299 patients. 596 (46%)
received TXA while 703 (54%) received control
treatment (placebo, lidocaine plus vasoconstrictors
or local anesthetics). Patients who were treated with
TXA were 3.5 times (OR 3.5, 95% CI 1.3e9.7) more
likely to achieve bleeding cessation at the ﬁrst
assessment. Patients treated with TXA had 63% (OR
0.37, 95% CI 0.20e0.66) less likelihood of returning
due to rebleeding at 24e72 h.
Limitations: Cochrane bias tool rated 4 of the
studies as possibly suffering from bias. They did not
include many studies that compared txa to placebo
and it is possible that TXA offers an overall low
treatment effect. Most studies were not double
blinded, potentially introducing bias. Not all studies
had robust demographic information such as the
presence of anticoagulation or hypertension.
Bottom Line: This meta analysis suggests TXA is
superior to other topical pharmacotherapy in the
management of epistaxis, but more study is needed
to see whether topical therapy in general should be
attempted over other management strategies such
as cautery, packing, or balloon tamponade.

12. Topic: Musculoskeletal
Question: Are muscle relaxants effective in the
management of acute low back pain?
Study: Abril L et al. The Relative Efﬁcacy of Seven
Skeletal Muscle Relaxants. An Analysis of Data
From Randomized Studies. J Emerg Med. 2022 Jan
20:S0736-4679(21)00839e8.
Methods: Planned analysis of 4 randomized,
double blind, placebo-controlled trials comparing
naproxen þ placebo to various muscle relaxants,
including tizanidine, cyclobenzaprine, baclofen,
metaxolone, diazepam, methocarbamol, and
orphenadrine. Primary outcome was change of
RolandeMorris Disability Questionnaire (RMDQ) at
1 week.
Results: Mean improvement in RMDQ per group
was placebo 10.5 (95% conﬁdence interval [CI]
9.5e11.5), baclofen 10.6 (95% CI 8.6e12.7), metaxalone 10.3 (95% CI 8.1e12.4), tizanidine 11.5 (95% CI
9.5e13.4), diazepam 11.1 (95% CI 9e13.2), orphenadrine 9.5 (95% CI 7.4e11.5), methocarbamol 8.1 (95%
CI 6.1e10.1), and cyclobenzaprine 10.1 (95% CI
8.3e12). The between-group differences were not
statistically signiﬁcantly different.
Limitations: Unlike typical meta-analysis, this
study did not undergo systematic review of databases and thus the studies selected may suffer from
selection bias. With that said, the quality of all
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studies selected was high. Additionally these studies
were conducted in 2 ERs in the Bronx, and may not
be generalizable to other populations. Older adults
were excluded from the studies.
Bottom Line: This is pretty good evidence that
muscle relaxants are of limited to no beneﬁt in the
management of low back pain.

13. Topic: Evidence-based medicine
Question: How many unbiased, high-quality
meta-analyses address issues of clinical importance
in emergency medicine?
Study: Parish AJ, Yuan DMK, Raggi JR, Omotoso
OO, West JR, Ioannidis JPA. An umbrella review of
effect size, bias, and power across meta-analyses in
emergency medicine. Acad Emerg Med. 2021;
28(12):1379e1388. doi:10.1111/acem.14,312.
Methods: Meta-analysis of meta-analyses (umbrella review) germane to emergency medicine via
comprehensive journal and database search from
1990 to 2020. Data was analyzed at the levels of the
individual studies and the meta-analysis summaries. Bias, quality, and power were analyzed
using standardized tools such as funnel plots,
Cohen's d, and GRADE analyses. Studies were
separated by those which measured mortality
versus other clinical outcomes.
Results: 431 meta-analyses of 3129 individual
studies across 350 topics were included. 39.0% of
meta-analyses and 28.4% of individual studies were
statistically signiﬁcant. Of the statistically signiﬁcant
results, only 9.5% of meta-analyses and 14.5% of
individual studies favored the control intervention.
41.3% of meta-analyses reported small effect sizes.
50.0% were rated low quality evidence by GRADE,
only 11.1% were rated high quality. Only 18.0% of
studies were adequately powered. No meta-analyses that measured a mortality outcome were
composed of randomized controlled trials,
adequately powered, statistically signiﬁcant, and
showed no evidence of bias.
Limitations: Signiﬁcant abstraction was required
for the appropriate analyses and may introduce
bias; some interventions (such as insulin for diabetic
ketoacidosis or deﬁbrillation for ventricular ﬁbrillation) are so dramatically beneﬁcial that randomized controlled trials are inappropriate and these
interventions would not be captured; analysis only
assessed primary outcomes.
Bottom Line: As in many ﬁelds, few emergency
medicine interventions have high-quality, unbiased
evidence supporting them. Care must be taken to
understand systemic sources of bias that exist
beyond methods and framing of individual papers,
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especially with new evidence. This is especially true
given the pressure to publish positive, ﬁnancially
lucrative, and otherwise personally or institutionally
beneﬁcial results.

14. Topic: Infectious disease/Bias
Question: Is there evidence of racial bias resulting
in delays in diagnosis of appendicitis in children?
Study: Goyal MK, Chamberlain JM, Webb M et al.
Racial and ethnic disparities in the delayed diagnosis of appendicitis among children. Acad Emerg
Med. 2021; 28(9):949e956. https://doi.org/10.1111/
acem.14142.
Methods: Multicenter retrospective cohort study
of children diagnosed with appendicitis identiﬁed
via the PECARN Registry, which tracks 7 pediatric
emergency departments in the United States, from
2014 to 2018. Children were identiﬁed via ICD codes
for appendicitis and were eligible if ethnicity data
was coded and patients did not leave prior to
completion of evaluation. Primary outcomes were
perforation (identiﬁed by ICD code), delayed diagnosis by bounceback visits with subsequent
appendicitis diagnosis, and whether diagnostic imaging was used in the prior visit in cases of delayed
diagnosis.
Results: 7298 children were eligible for inclusion.
35.2% of children had perforation, with non-Hispanic Black patients having a higher ratio than nonHispanic White patients (36.5% versus 34.9%,
aOR ¼ 1.21, CI > 1). 2.8% of patients had a related
emergency visit in the previous 7 days, with children of minority ethnicity having higher rates (4.7%
for non-Hispanic Black, OR ¼ 2.45; 4.0% for Hispanic, OR ¼ 2.07). Non-Hispanic Black patients with
delayed diagnosis had a lower likelihood of imaging
at initial presentation (28.6% versus 35.9% for nonHispanic White patients).
Limitations: Cases were identiﬁed by ICD codes
which may miss some cases, many variables were
analyzed and multiple models were run which increases risk of statistical bias.
Bottom Line: Racial bias leads to delayed diagnosis and missed diagnosis of appendicitis in children. This adds to the growing literature
demonstrating how racial and other forms of bias
permeate medicine and cause harm.

Outpatient Treatment in Mild Acute Diverticulitis
(DINAMO-study): A Multicentre, Randomised,
Open-label, Noninferiority Trial. Ann Surg. 2021
Nov 1; 274(5):e435-e442.
Methods: Prospective, multicenter, open-label,
noninferiority, randomized controlled trial of ED
patients with acute diverticulitis conducted at 15
hospitals in Spain. Adult patients between the ages
of 18 and 90 were included. Patients were excluded
if they had signiﬁcant comorbidities, immunosuppression, a previous episode of AD in the past 3
months, recent antibiotic treatment, poor symptom
control in the ED, or met SIRS criteria. Patients were
only included if they met the Neff 0 criteria for mild,
uncomplicated diverticulitis All patients received a
CT scan prior to enrollment and were then randomized to antibiotics (ATB), or no ATB. Primary
endpoint was hospital admission. Secondary endpoints included ED revisits, pain control, and
emergency surgery. NSAIDs were prescribed to all
patients for pain control.
Results: 480 patients met inclusion criteria. No
signiﬁcant difference in the primary or any of the
secondary outcomes was observed. Hospitalization
rates were 14/238 (5.8%) in the ATB-Group and 8/
242 (3.3%) in the Non-ATB-Group [mean difference
2.58%, 95% conﬁdence interval (CI) 6.32 to 1.17].
Revisits were: 16/238 (6.7%) in the ATB-Group and
17/242 (7%) in the Non-ATB-Group 4.83. Poor pain
control at 2 days follow-up was 13/230 (5.7%) in the
ATB-Group and 5/221 (2.3%) in the Non-ATBGroup.
Limitations: There was no placebo used and both
clinicians and patients were aware of group
randomization. Many exclusion criteria mean results are not generalizable to a large number of
patients we see with acute diverticulitis.
Bottom Line: This is another in a series of studies
supporting outpatient treatment of uncomplicated
diverticulitis without antibiotics. UpToDate recently
changed their guidance on this subject to recommend against prescribing antibiotics for outpatient
treatment of uncomplicated diverticulitis. It is
important to consider local practice patterns and to
carefully screen patients for exclusion criteria before
utilizing this approach. This may be a good area for
shared decision making with patients.

16. Topic: COVID-19
15. Topic: Treatment modalities
Question: Should antibiotics be prescribed for
mild acute diverticulitis (AD)?
Study: Mora-L
opez L et al. DINAMO-study
Group. Efﬁcacy and Safety of Nonantibiotic

https://scholar.rochesterregional.org/advances/vol2/iss2/11
DOI: 10.53785/2769-2779.1105

Question: Is there a beneﬁt to antiplatelet agents
in the treatment of critically ill patients with
COVID-19?
Study: REMAP-CAP Writing Committee for the
REMAP-CAP Investigators, Bradbury CA et al.
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Effect of Antiplatelet Therapy on Survival and
Organ Support-Free Days in Critically Ill Patients
With COVID-19: A Randomized Clinical Trial.
JAMA. 2022 Apr 5; 327(13):1247e1259. doi: 10.1001/
jama.2022.2910.
Methods: This was an adaptive platform trial
testing multiple interventions. Patients were randomized to receive either open-label aspirin, a
P2Y12 inhibitor, or no antiplatelet therapy. Interventions were continued in the hospital for a
maximum of 14 days and were in addition to anticoagulation thromboprophylaxis. The primary
endpoint was organ support-free days (days alive
and free of intensive care unit-based respiratory or
cardiovascular organ support) within 21 days. There
were 13 secondary outcomes, including survival to
discharge and major bleeding to 14 days.
Results: 1557 critically ill patients with COVID-19
were included, 1549 of whom completed the trial.
The median for organ support-free days was 7 in
both the antiplatelet and control groups (medianadjusted OR, 1.02 [95% credible interval {CrI},
0.86e1.23]; 95.7% posterior probability of futility).
The proportions of patients surviving to hospital
discharge were 71.5% (723/1011) and 67.9% (354/521)
in the antiplatelet and control groups, respectively
(median-adjusted OR, 1.27 [95% CrI, 0.99e1.62];
adjusted absolute difference, 5% [95% CrI, 0.2%e
9.5%]; 97% posterior probability of efﬁcacy). Among
survivors, the median for organ support-free days
was 14 in both groups. Major bleeding occurred in
2.1% and 0.4% of patients in the antiplatelet and
control groups (adjusted OR, 2.97 [95% CrI,
1.23e8.28].
Limitations: Open-label trial. The multiple secondary outcomes limit the ability to make deﬁnitive
conclusions for many of these outcomes, due to
under-powering. Patients received varying types of
antiplatelet agents, resulting in substantial heterogeneity and limiting the ability to draw conclusions
deﬁnitively for any one antiplatelet agent.
Bottom Line: There was no beneﬁt for the addition
of anti-platelet agents to the treatment of critically ill
patients with COVID-19, and there was an increased
risk of bleeding in the group treated with antiplatelet drugs.

With Acute Ischemic Stroke Treated With Alteplase.
JAMA. 2022 Feb 22; 327(8):760e771.
Methods: Retrospective cohort study of 163,038
patients who received intravenous alteplase for
acute stroke. 2207 were taking NOACs in the week
prior to receiving alteplase and 160,831 did not.
Primary outcome was symptomatic intracranial
hemorrhage within 36 h of alteplase administration.
Secondary outcomes included mortality and functional outcomes.
Results: Of 163,038 patients treated with intravenous alteplase 2207 (1.4%) were taking NOACs and
160,831 (98.6%) were not taking anticoagulants
prior to their stroke. The unadjusted rate of symptomatic intracranial hemorrhage was 3.7% (95% CI,
2.9%e4.5%) for patients taking NOACs vs 3.2%
(95% CI, 3.1%e3.3%) for patients not taking anticoagulants. After adjusting for baseline clinical
factors, the risk of symptomatic intracranial hemorrhage was not signiﬁcantly different between
groups (adjusted odds ratio [OR], 0.88 [95% CI, 0.70
to 1.10]; adjusted risk difference [RD], 0.51% [95%
CI, 1.36%e0.34%]). There were no signiﬁcant
differences in the secondary safety outcomes,
including inpatient mortality (6.3% for patients
taking NOACs vs 4.9% for patients not taking anticoagulants; adjusted OR, 0.84 [95% CI, 0.69 to
1.01]; adjusted RD, 1.20% [95% CI, 2.39% to
0%]). Of the secondary functional outcomes, 4 of 7
showed signiﬁcant differences in favor of the
NOAC group after adjustment, including the proportion of patients discharged home (45.9% vs
53.6% for patients not taking anticoagulants;
adjusted OR, 1.17 [95% CI, 1.06 to 1.29]; adjusted
RD, 3.84% [95% CI, 1.46%e6.22%]).
Limitations: Retrospective study. Differences in
baseline characteristics in DOAC vs no DOAC
groups introduces confounding. There could be selection bias in which patients taking DOACs
received alteplase. Could it be only patients that
forgot to take their last dose of DOAC were ones
that were offered TPA? We don't know.
Bottom Line: This is some evidence that taking
DOACs prior to TPA might not be the contraindication we've previously thought it to be, but more
evidence is needed for major practice change.

17. Topic: Neurology

18. Topic: Cardiology

Question: Is recent DOAC use associated with an
increased risk of intracranial hemorrhage prior to
alteplase administration in acute stroke?
Study: Kam W et al. Association of Recent Use of
Non-Vitamin K Antagonist Oral Anticoagulants
With Intracranial Hemorrhage Among Patients

Question: Can the Modiﬁed Sgarbossa Criteria be
used to detect myocardial infarction (MI) in ventricular paced rhythms with high accuracy?
Study: Dodd KW et al. Electrocardiographic
Diagnosis of Acute Coronary Occlusion Myocardial
Infarction in Ventricular Paced Rhythm Using the

Published by RocScholar, 2022

9

Advances in Clinical Medical Research and Healthcare Delivery, Vol. 2 [2022], Iss. 2, Art. 11

Modiﬁed Sgarbossa Criteria. Ann Emerg Med. 2021
Oct; 78(4):517e529.
Methods: Retrospective case control study of patients presenting to 16 international cardiac care
centers between Jan 2008e2018. There were two
control groups, one of “non-occlusion MI-angio
group” who had presumed type I MI but did not
meet STEMI criteria and “no occlusion MI group”
which consisted of randomly selected ED patients
without occlusion MI.
Results: There were 59 occlusion myocardial
infarction, 90 non-occlusion myocardial infarctionangio, and 102 no occlusion myocardial infarction
subjects. For the diagnosis of occlusion myocardial
infarction, the Modiﬁed Sgarbossa Criteria (MSC)
were more sensitive than the original Sgarbossa
criteria (sensitivity 81% [95% conﬁdence interval
[CI] 69 to 90] versus 56% [95% CI 42 to 69]). For
the no occlusion myocardial infarction control
group of ED patients, additional test characteristics of MSC and original Sgarbossa criteria,
respectively, were as follows: speciﬁcity 96% (95%
CI 90 to 99) versus 97% (95% CI 92 to 99); negative
likelihood ratio (LR) 0.19 (95% CI 0.11 to 0.33)
versus 0.45 (95% CI 0.34 to 0.65); and positive LR
21 (95% CI 7.9 to 55) versus 19 (95% CI 6.1 to 59).
For the non-occlusion myocardial infarction angio

https://scholar.rochesterregional.org/advances/vol2/iss2/11
DOI: 10.53785/2769-2779.1105

control group, additional test characteristics of
MSC and original Sgarbossa criteria, respectively,
were as follows: speciﬁcity 84% (95% CI 76 to 91)
versus 90% (95% CI 82 to 95); negative LR 0.22
(95% CI 0.13 to 0.38) versus 0.49 (95% CI 0.35 to
0.66); and positive LR 5.2 (95% CI 3.2 to 8.6) versus
5.6 (95% CI 2.9 to 11).
Limitations: The study was retrospective given the
low prevalence of patients with both a ventricular
paced rhythm AND occlusion MI. Additionally
given the difﬁculty in ﬁnding subjects, the results
had very wide conﬁdence intervals that were nearly
overlapping. The trend favoring modiﬁed sgarbossa
across all groups is pretty convincing however.
Differences in single-versus biventricular pacing in
the no occlusion/occlusion groups possibly introduces bias.
Bottom Line: Although this study has ﬂaws, it is
pretty decent evidence that Modiﬁed Sgarbossa has
reasonable test characteristics and outperforms
traditional Sgarbossa in evaluating for MI in ventricular paced rhythms.
Conﬂict of interest
We, the authors, have no conﬂicts of interest to
disclose.
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